Amylin Pharmaceuticals to Present New Data and Insights From the Company’s Diabetes Programs at ADA 2010
Amylin Pharmaceuticals, Inc. today announced that the Company will present data for its FDA-approved diabetes drugs, BYETTA® injection and SYMLIN® injection, and its investigational diabetes drug candidate BYDUREON⢠at the American Diabetes Association’s 70th Annual Scientific Sessions being held in Orlando, FL from June 25 to June 29.
Diabetes help with home remedies “diabetes”